FRA:ZEG • GB0009895292
Taking everything into account, ZEG scores 5 out of 10 in our fundamental rating. ZEG was compared to 52 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROIC | 13.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Altman-Z | 3.77 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.53 | ||
| Fwd PE | 18.05 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.09 | ||
| EV/EBITDA | 16.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
FRA:ZEG (2/5/2026, 7:00:00 PM)
160.7
+0.95 (+0.59%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.53 | ||
| Fwd PE | 18.05 | ||
| P/S | 5.03 | ||
| P/FCF | 34.09 | ||
| P/OCF | 20.28 | ||
| P/B | 6.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.14 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROCE | 16.8% | ||
| ROIC | 13.63% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 59.47% | ||
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% | ||
| FCFM | 14.76% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 103% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 10.65 | ||
| Cash Conversion | 73.79% | ||
| Profit Quality | 84.79% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 3.77 |
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 23.53 and the Price/Book (PB) ratio is 6.07.
The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 30.41% in the next year.